Purpose of Review <p>Inflammatory bowel disease (IBD) poses a looming global health burden characterized by increasing prevalence and healthcare costs. This is despite significant advances in available therapeutics and disease monitoring strategies over the past 25 years. A precision medicine approach promises to enhance personalized medicine through improved prediction models, precise diagnoses, and individualized treatment strategies.</p> Recent Findings <p>Recent advances in artificial intelligence (AI) are now being incorporated into endoscopy, histology, and radiology research with the aim of improving objective, reproducible, and timely assessments of IBD. High-throughput platforms – including genetics (e.g. single nucleotide polymorphisms and polygenic risk scores), messenger RNA expression (e.g. transcript sets), and comprehensive protein and metabolite measurements – have the potential to uncover biomarkers that aim to resolve ambiguous disease states, provide risk stratification (e.g. of disease complications and response to treatment), and reveal mechanistic insight.</p> Summary <p>This review highlights recent advances in AI and high-dimensional molecular profiling in IBD, focusing on methodological and translational challenges that will need to be addressed to fully realize precision medicine’s potential in clinical care.</p>